It's a rare stock that can actualy see it's 52 week high in the distance and have a good chance of getting there. Harmony is one such stock.
rev of $364 mil <-- they make money. This can often and ironically be a negative thing in Biotech investing... some day I'll get into it. But Biotechs are birthed with much fanfare they stow away cash from investors along the way as they dribble out Press Releases about long shot ideas... but once the product is out and the cash is coming in rather than cheer to the heavens, Biotech investors often start looking for the next birth.
EBITDA 131.M
Where this idea gets interesting:
Float 31 mil aprox
Shares Short (Sep 30, 2022) 6.06M
Short Ratio (Sep 30, 2022) 11.76
Short % of Float (Sep 30, 2022)---> 21.24%That's as of Sept maybe Van can get a fresher number.
Harmony Biosciences Holdings, Inc. (HRMY)
NasdaqGM - NasdaqGM Real Time Price.
47.63+0.99(+2.12%)
At close: October 13 04:00PM EDT
50.50+2.87(+6.03%)<---------------
Pre-Market:08:00AM EDT
Jefferies upgrades 'undervalued' Harmony Biosciences to Buy 07:59 HRMY As previously reported, Jefferies analyst Chris Howerton upgraded Harmony Biosciences to Buy from Hold with a price target of $61, up from $57. With an estimated 34% annualized revenue growth rate, which Howerton calls out as "the highest among biotech stocks with positive net income," the shares are "undervalued." He sees "no slowing down" of Wakix's linear uptake on an annualized basis and thinks it deserves a higher premium for its growth, Howerton said, adding that he sees Harmony "quickly filling the piggy bank and looking for somewhere to put it" and that it is not hard for him to imagine an accretive acquisition at current valuations. Show Related Items >>
rev of $364 mil <-- they make money. This can often and ironically be a negative thing in Biotech investing... some day I'll get into it. But Biotechs are birthed with much fanfare they stow away cash from investors along the way as they dribble out Press Releases about long shot ideas... but once the product is out and the cash is coming in rather than cheer to the heavens, Biotech investors often start looking for the next birth.
EBITDA 131.M
Where this idea gets interesting:
Float 31 mil aprox
Shares Short (Sep 30, 2022) 6.06M
Short Ratio (Sep 30, 2022) 11.76
Short % of Float (Sep 30, 2022)---> 21.24%That's as of Sept maybe Van can get a fresher number.
Harmony Biosciences Holdings, Inc. (HRMY)
NasdaqGM - NasdaqGM Real Time Price.
47.63+0.99(+2.12%)
At close: October 13 04:00PM EDT
50.50+2.87(+6.03%)<---------------
Pre-Market:08:00AM EDT
Jefferies upgrades 'undervalued' Harmony Biosciences to Buy 07:59 HRMY As previously reported, Jefferies analyst Chris Howerton upgraded Harmony Biosciences to Buy from Hold with a price target of $61, up from $57. With an estimated 34% annualized revenue growth rate, which Howerton calls out as "the highest among biotech stocks with positive net income," the shares are "undervalued." He sees "no slowing down" of Wakix's linear uptake on an annualized basis and thinks it deserves a higher premium for its growth, Howerton said, adding that he sees Harmony "quickly filling the piggy bank and looking for somewhere to put it" and that it is not hard for him to imagine an accretive acquisition at current valuations. Show Related Items >>
